The MarketWatch News Department was not involved in the creation of this content.-- Newly discovered drug leverages the power of Pattern Discovery Engine(TM) (PDE) and is an exten ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells—also known as "zombie cells"—in diabetic kidney ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

Eli Lilly & Co. warned that the active ingredient in its weight-loss blockbuster Zepbound could pose a risk to patients when ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Eli Lilly and Co on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells – also known as "zombie cells" – in diabetic kidney ...

GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today ...